<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>FLOWERS Trial &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/flowers-trial/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 13 Jan 2026 11:25:35 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>FLOWERS Trial &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial</title>
		<link>https://bioengineer.org/osimertinib-%c2%b1-savolitinib-in-met-egfr-nsclc-trial/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 13 Jan 2026 11:25:30 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[First-Line NSCLC Therapy** **Kısa Açıklama:** 1. **EGFR-Mutant NSCLC:** Makalenin odaklandığı temel kanser türü ve alt grubu. 2. **MET Aberrations:** Çalışman]]></category>
		<category><![CDATA[FLOWERS Trial]]></category>
		<category><![CDATA[İşte içerikle en uyumlu 5 etiket: **EGFR-Mutant NSCLC]]></category>
		<category><![CDATA[MET Aberrations]]></category>
		<category><![CDATA[Osimertinib-Savolitinib Combination]]></category>
		<guid isPermaLink="false">https://bioengineer.org/osimertinib-%c2%b1-savolitinib-in-met-egfr-nsclc-trial/</guid>

					<description><![CDATA[A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for non-small cell lung cancer (NSCLC), specifically targeting patients harboring epidermal growth factor receptor (EGFR) mutations alongside MET gene aberrations. Published recently in Nature Communications, the FLOWERS trial meticulously explored the efficacy of osimertinib — a third-generation EGFR tyrosine kinase inhibitor [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316461</post-id>	</item>
	</channel>
</rss>
